1. In Vivo
  2. >>Innovation

Science Matters: Setting The Stage For Using Wearables In Oncology Drug Development

 
• By Mark Ratner

Digital biomarkers using data collected with wearable devices are making their way into clinical trials, largely in cardiovascular, respiratory and rare disease settings around physical activity metrics.

Lightbulb
• Source: Shutterstock

Applications in oncology are moving at a more deliberate pace owing to the distinctive nature of cancer patients’ needs. Less impetus to develop novel digital outcomes measures also exists in oncology as tumor-associated outcomes rule the roost. Conversely, the toxic nature of cancer treatments, the duration of treatment, and the variety of drugs and therapeutic regimens available for the many different cancer subtypes elevates the need for objective quality of life (QoL) assessments, where wearables can play an important role.

“Wearables give us insight into patient experiences that we don’t have otherwise, because the data is so objective and dynamic...

More from Innovation

BioBytes: AI-Related Deals In Q3 ‘25

 
• By David Wild

The third quarter of 2025 included a host of venture financings for AI-focused biotechs and several $1bn+valued alliances.

ALS Drug Development Case Studies: MediciNova And Coya Therapeutics

 
• By David Wild

MediciNova and Coya Therapeutics are advancing ALS candidates as regulatory flexibility and Phase II pipeline concentration create a pivotal market inflection point.

Beyond Data Sharing: How Biopharma Is Rewriting The Rules Of Collaboration

 
• By David Wild

Pharmaceutical companies are creating collaborative AI platforms that simulate drug trials, accelerate discovery and democratize access to proprietary datasets.

How 250 Million Protein Measurements Could Transform Neurodegeneration Drug Development

 
• By Joanne Shorthouse

A massive new proteomics dataset promises to accelerate target identification, biomarker discovery and precision medicine approaches in Alzheimer's, Parkinson's and other neurodegenerative diseases.

More from In Vivo

Too Big To Refill? Pharma’s Race To Replace $300bn In Expiring Revenues

 
• By Daniel Chancellor

An extensive list of blockbuster drugs face patent expiry over the next six years, putting significant revenues at risk for major companies. While Eli Lilly and Novo Nordisk are reaping the rewards of GLP-1 successes, other large pharmas face steep challenges in closing their growth gaps.

Beyond Cebranopadol: Tris Pharma’s 25-Year Legacy In Drug Delivery Innovation

 
• By David Wild

Tris Pharma may be making headlines for its novel pain medication cebranopadol, but the New Jersey-based company's story extends far beyond a single asset.

Beyond Data Sharing: How Biopharma Is Rewriting The Rules Of Collaboration

 
• By David Wild

Pharmaceutical companies are creating collaborative AI platforms that simulate drug trials, accelerate discovery and democratize access to proprietary datasets.